United Kingdom Pharmacokinetics Services Market Insight
The United Kingdom Pharmacokinetics Services Market is growing at an 6.51% CAGR, driven by rising clinical trial outsourcing, expansion of precision medicine, increasing biologics and biosimilar development, and strong demand for ADME studies. Pharmaceutical R&D growth, regulatory requirements, and advanced bioanalytical technologies further enhance drug development efficiency and safety assessment capabilities.
United Kingdom Pharmacokinetics Services Market Insights Forecasts to 2035
- The United Kingdom Pharmacokinetics Services Market Size Was Estimated at USD 47.32 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.51% from 2025 to 2035
- The United Kingdom Pharmacokinetics Services Market Size is Expected to Reach USD 88.9 Million by 2035
Notable Insights for United Kingdom Pharmacokinetics Services Market
- By service type, bioanalytical and ADME studies dominated, accounting for approximately 50–60% share in 2024, driven by strong demand in early-stage drug development.
- By molecule type, small molecules held approximately 60–65% share, though biologics are rapidly growing due to increasing monoclonal antibody and cell therapy pipelines.
- Approximately 55–60% of UK pharmaceutical companies outsource pharmacokinetics (PK) and pharmacodynamics (PD) services to CROs to reduce development timelines and costs.
- Around 40–45% of PK studies are linked to oncology and central nervous system (CNS) drug development, reflecting high clinical research activity in these therapeutic areas.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Pharmacokinetics Services Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Pharmacokinetics Services Market
- Covance (Labcorp Drug Development)
- Charles River Laboratories
- Thermo Fisher Scientific
- ICON plc
- Parexel International
- SGS SA
- Syneos Health
- Evotec SE
- Others
Recent Developments:
- In March 2026, UKRI and NC3Rs promote AI and in silico pharmacokinetics models, supporting non-animal drug testing. £2M funding advances human-relevant preclinical PK systems, reducing dog and primate study reliance.
- In April 2026: The Medicines and Healthcare products Regulatory Agency and National Institute for Health and Care Excellence launched an aligned pathway enabling parallel licensing and appraisal, accelerating patient access by up to six months.
Market Segmentation:
United Kingdom Pharmacokinetics Services Market, By Service Type
- Bioanalytical Services
- ADME Studies
- Drug Metabolism Studies
- Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling
- Others
United Kingdom Pharmacokinetics Services Market, By Molecule Type
- Small Molecules
- Large Molecules (Biologics)
United Kingdom Pharmacokinetics Services Market, By End User
- Pharmaceutical & Biotechnology Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
United Kingdom Pharmacokinetics Services Market, By Therapeutic Area
- Oncology
- CNS Disorders
- Infectious Diseases
- Cardiovascular Diseases
- Others
Expert Views:
The UK Pharmacokinetics Services Market is expected to grow strongly due to increasing complexity in drug development and rising outsourcing of clinical and preclinical research activities. Experts highlight that pharmacokinetics and pharmacodynamics studies are essential for optimizing drug safety, dosing, and efficacy, particularly in biologics and precision medicine. Expanding clinical trial activity in oncology and rare diseases is further driving demand. Advancements in bioanalytical technologies, modeling software, and regulatory requirements are expected to shape future market growth through 2035.